Potentiation of 2-deoxy-D-glucose antinociception, but not hyperphagia by zolantidine, a histamine (H2) receptor antagonist

• Published in: Pharmacology, biochemistry and behavior Vol. 41; no. 2; p. 371
• Main Authors: Koch, J E, Hough, L B, Bodnar, R J
• Format: Journal Article
• Language: English
• Published: United States 01-02-1992
• Subjects: Animals; Benzothiazoles; Deoxyglucose - pharmacology; Histamine H2 Antagonists - pharmacology; Hot Temperature; Hyperphagia - drug therapy; Male; Nociceptors - drug effects; Phenoxypropanolamines; Piperidines - pharmacology; Rats; Rats, Inbred Strains; Thiazoles - pharmacology
• ISSN: 0091-3057
• DOI: 10.1016/0091-3057(92)90113-T

Antagonism of the histamine (H2) receptor reduces antinociception induced by naloxone-resistant foot-shock, naloxone-sensitive foot-shock, and morphine with a rank-order potency similar to their H2 antagonism. The antimetabolic glucose analog 2-deoxy-D-glucose (2DG) produces antinociceptive and hyperphagic responses that dissociate from each other and are in part mediated by opioid systems. The present study determined the effects of the brain-penetrating H2 receptor antagonist zolantidine (ZOL) on 2DG antinociception on the tail-flick and jump tests, as well as on 2DG hyperphagia, in rats. ZOL (0.01-1 mg/kg) potentiated the antinociceptive responses induced by a moderate (450 mg/kg) dose of 2DG, but had lesser effects upon antinociception induced by a lower (100 mg/kg) 2DG dose. ZOL itself slightly increased jump thresholds, but not tail-flick latencies. Combinations of ZOL and 2DG produced supraadditive antinociception, even though ZOL failed to significantly shift the 2DG dose-response curve to the left. In contrast, ZOL failed to alter basal intake or 2DG hyperphagia, supporting previous evidence implicating the H1 but not the H2 receptor in these effects. These results further dissociate the antinociceptive and hyperphagic effects of 2DG, and also support previous results indicating both pro- and antinociceptive roles for H2 receptors.